Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer’s, which was positive. We have been selected to develop the phase III trial with this Eisai drug.
Related Stories
21 de noviembre de 2023
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
16 de enero de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
3 de junio de 2021
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
3 de junio de 2021
This study could improve the efficacy and safety of the products being evaluated to try…
22 de julio de 2020
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
12 de diciembre de 2019
Grifols has reported to the press the positive result of the AMBAR trial in patients…
5 de noviembre de 2019
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
20 de septiembre de 2019
Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in…